



NGOC Clinical Trials List - Printable Version

Head and Neck (C00-C14)

1. Locally Advanced
2. 1st Line Recurrent / Metastatic
3. Previously Treated

Esophagus/Gastric (C15-C16)

1. Stage II- IV, Neo-adjuvant
2. First Line, Recurrent or Metastatic
 - a. **AZ D702AC00001 (Artemide-Gastric01) A Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine**
 - i. Arm A: Rilvegostomig + T-Dxd + Investigator's Choice: 5-FU or Capecitabine
 - ii. Arm B: Pembro + trastuzumab + Investigator's choice: Cisplatin+ 5FU or CAPOX+capecitabine
 - iii. Arm C: Rilvegostomic (750mg IV Q3w) + Trastuzumab + Investigator's Choice: Cisplatin+5FU OR CAPOX+Capecitabine
3. Previously Treated

Open 8/12/25

Biliary (K83.9)

1. First Line Therapy
 - a. **AZ D702NC00001 A Global Phase III Study of Rilvegostomig Plus Chemotherapy for First-**
 - i. Arm A: Rilvegostomig 750mg on D1 of each Q3W+ Gemcitabine 1000 mg/m2 IV Q3W plus cisplatin 25 mg/m2 IV Q3W will be administered on D1 and D8 of each cycle starting on C1D1 for up to 8 cycles
 - ii. Arm B: Durvalumab 1500mg on D1 of each Q4W cycle +Gemcitabine 1000 mg/m2 IV Q3W plus cisplatin 25 mg/m2 IV Q3W will be administered on D1 and D8 of each cycle starting on C1D1 for up to 8 cycles

Open 3/25/26

Pancreas (C25)

1. Adjuvant / NeoAdjuvant
2. 1st Line, Metastatic
 - a. **BMS CA240-0030 (MountainTAP) Study of BMS-986504 in Combination with Nab-p/Gem versus Placebo in Co**
 - i. Phase 2 Dose Selection Arm A: BMS-986504 400mg + Nab-Pac + Gem
 - ii. Phase 2 Dose Selection Arm B: BMS-986504 600mg + Nab-Pac + Gem
 - iii. Phase 2 Dose Selection Arm C: BMS-986504 400mg Placebo + Nab-Pac + Gem
 - iv. Phase 2 Dose Selection Arm D: BMS-986504 600mg Placebo + Nab-Pac + Gem
 - v. NOT YET OPEN Phase 3 Arm E: BMS-986504 Optimal Dose + Nab-Pac + Gem
 - vi. NOT YET OPEN Phase 3 Arm F: BMS-986504 Optimal Dose Placebo + Nab-Pac + Gem
3. Previously Treated

On Hold 5/5/26

Colon & Rectum (C18-C20)

1. Stage III, Resected Colon, Adjuvant
2. Stage IV, Metastatic, 1st Line, Colon or Rectum
3. Metastatic, 1st Line, Colorectal
 - a. **BMS CA266-0003 (ROSETTA CRC-203) Punitamig in Combination with Chemotherapy Versus Bevacizumab in Combi**
 - i. Closed-Phase 2 Arm A1: punitamig (BMS-986545) Dose Level 1, Day 1 + FOLFOX or FOLFIRI,Q2W
 - ii. Closed-Phase 2 Arm A2: punitamig (BMS-986545) Dose Level 2, Day 1 + FOLFOX or FOLFIRI,Q2W
 - iii. Closed-Phase 2 Arm B: bevacizumab, Day 1 + FOLFOX or FOLFIRI, Q2W
 - iv. NOT OPEN Phase 3 Arm C: punitamig RP3D, Day 1 + FOLFOX or FOLFIRI, Q2W; or punitamig RP3D + CAPOX, Q3W
 - v. NOT OPEN Phase 3 Arm D: bevacizumab, Day 1 + FOLFOX or FOLFIRI, Q2W or bevacizumab + CAPOX, Q3W
4. Metastatic, 3rd Line, Colon
5. Metastatic 2nd or 3rd Line, KRAS Mutated
6. Metastatic 2nd or 3rd Line, KRAS Wild Type
7. Refractory

Pending 4/28/26

Lung, Squamous Cell (C34)

1. Stage IV, Metastatic
2. Second Line

Lung, Non-Small Cell (C34)

1. Stage IB, II, IIIA; Adjuvant
2. Stage 1B, II, Resectable IIIA
3. Stage II-III Resectable or Resected
 - a. **BI 1479-0032 (Beamion Lung-3) A Phase 3, Beamion LUNG-3: A study to test whether zongertinib helps**
 - i. Arm A: Zongertinib (BI 1810631) 120mg po qd
 - ii. Arm B: Physicians Choice(Nivolumab 480mg, pembrolizumab 200mg, atezolizumab 1200mg, or durvalumab 1500mg)
4. Stage IIIA-IIIIB, Locally Advanced, Unresectable
5. Stage IIB-IIIIB Resected and Chemotherapy-Naive Stage IV
6. Stage IV, Metastatic
7. First Line- Metastatic
 - a. **AZ D702GC00001 Artemide Lung-04 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy**
 - i. Arm A: Rilvegostomig 750 mg IV Q3W
 - ii. ArmB: Pembrolizumab 200 mg IV Q3W
 - b. **BMS CA266-0002(ROSETTA Lung-202) A Study of Punitamig Versus Pembrolizumab in Participants With Previou**
 - i. Arm A: Punitamig 1200 mg (if body weight < 50 kg) or 1500 mg (if body weight ≥ 50 kg) as a 60-minute IV infusion every 3 weeks (Q3W)
 - ii. Arm B: Pembrolizumab 200 mg as a 60-minute IV infusion every 3 weeks (Q3W)
 - c. **BMS CA239-0004 (KRYSTAL-4) Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembro**
 - i. Arm A: Adagrasib 400mg BID + pemetrexed 500mg/m2 Q3W (until PD or unacceptable toxicity) + [cisplatin 75mg/m2 OR carboplatin AUC 5mg/mL/min Q3W (4 cycles)] + pembrolizumab 200mg Q3W (up to 24 months)
 - ii. Arm B: Placebo + pemetrexed 500 mg/m2 Q3W (until PD or unacceptable toxicity) + [cisplatin 75 mg/m2 OR carboplatin AUC 5 mg/mL/min Q3W (4 cycles)] + pembrolizumab 200 mg Q3W (up to 24 months)
8. 2nd or 3rd Line
9. Metastatic, Previously Treated
 - a. **AbbV M25-274 (TELImet NSCLC-04) A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab**
 - i. Arm A: Telisotuzumab vedotin 1.9 mg/kg Q2W
 - ii. Arm B: Telisotuzumab vedotin 1.6 mg/kg Q2W
 - iii. Arm C: Telisotuzumab vedotin 1.6 mg/kg Q2W x 4 cycles then 1.9 mg/kg Q2W
 - b. **AZ D763QC00001 (TROPION-Lung17) Datopotamab Deruxthen or Docetaxel in Previously Treated TROP2-posit**
 - i. Arm A: Dato-DXd 6mg/kg IV q3w
 - ii. Arm B: Docetaxel 75mg/m2 IV q3w

Open 3/19/26

Open 1/7/26

Open 4/15/26

Open 5/19/26

Open 10/20/25

Open 11/13/25

Mesothelioma (C45)

1. Extensive Stage, Small Cell Lung Ca

- a. **BMS CA245-0001 A Randomized, Double-Blind, Multicenter Phase 3 Trial**
 - i. Arm A: BMS-986489 420mg/nivolumab 360 mg IV+carboplatin+etoposide
 - ii. Arm B: atezolizumab 1200mg IV+carboplatin+etoposide

Open 1/24/25

Lung, Small Cell (C34)

2. Previously Treated

Breast, Adjuvant (C50)

1. NeoAdjuvant, Stage I, II, III
2. Adjuvant

a. GS-US-595-6184 (ASCENT-05) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govite

- i. Arm A: Sacituzumab Govitecan 10mg/kg IV Days 1 and 8 + Pembrolizumab 200mg IV Day 1 Q3W X 8 cycles
- ii. Arm B: Treatment of Physician's Choice: Pembrolizumab 200mg IV Day 1 Q3 weeks X 8 cycles OR Pembrolizumab 200 mg IV Day 1 and Capecitabine 1000 mg/m2 PO BID D1-D14 Q3 Weeks X 8 cycles

Open 1/31/23

Breast, Her-2 Positive (C50)

1. NeoAdjuvant HER-2 Positive
2. Adjuvant, HER-2 Positive
3. Metastatic, HER-2 Positive, 1st Line
4. Metastatic, Previously Treated, Her-2 Positive

Breast, Advanced (C50)

1. Stage IV, Metastatic, 1st Line

a. RGN WO45654 (INAVO123) A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED

- i. Arm A: Inavolisib 9mg tablet PO QD days 1-28 of 28 day cycle + + letrozole 2.5mg PO QD + Investigator's choice - palbociclib 125mg PO QD D1-21 of 28 or ribociclib 600mg D1-21 of 28d cycle
- ii. Arm B: Placebo tablet PO QD days 1-28 of 28 day cycle + + letrozole 2.5mg PO QD + Investigator's choice - palbociclib 125mg PO QD D1-21 of 28 or ribociclib 600mg D1-21 of 28d cycle

2. Stage IV, Metastatic, ER -
3. Stage IV, Metastatic, Previously Treated
4. Stage IV, Metastatic, Triple Negative Breast Cancer

Open 5/23/25

Breast, ER Positive (C50)

1. Adjuvant
2. Metastatic, First Line
3. Metastatic, Prior Hormonal Therapy

Melanoma (C43)

1. Adjuvant
2. Locally advanced or Metastatic
3. Previously Treated

Ovarian (C56)

1. Previously Treated

Bladder (C67)

- 1.
2. Urothelial

Renal (C64)

1. Adjuvant, Phase III
2. First Line Treatment, Advanced or Metastatic
3. Advanced, Metastatic

a. MK 6482-034 A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintin

- i. Arm 1: Belzutifan 120 mg qd+ Zanzalintinib 60 mg qd
- ii. Arm 2: Belzutifan 120 mg qd+Placebo

4. Previously Treated

Pending 5/29/26

Accrual = 3

Prostate (C61)

1. Hormone Refractory, 1st Line
2. 1st line Metastatic
3. Metastatic, 2nd Line Prostate
4. Hormone Refractory; Bone Predominant 3rd Line or Greater

Sarcoma (C46-C49)

1. Sarcoma, Previously Treated

Adrenal (C74)

1. Previously Treated

Lymphoma (C82-C88)

1. Indolent, previously treated
2. Follicular, First Line
3. Indolent, Relapsed
4. Relapsed or Refractory; DLBCL, FL
5. Large Cell Lymphoma, Relapsed/Refractory
6. Relapsed and Refractory Follicular Lymphoma

a. BMS CA073-1003 A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Ef

- i. Arm A: R-Golca 0.4mg D1-14/48 days+Rituximab x5cycles followed by golcadomide monotherapy for up to 12 cycles of toral therapy
- ii. Arm B: R-Len 20mg, Days 1-21, cycles 1-12,rituximab 375mg/m2, Days 1,8,15,and 22 in cycle 1; Day 1 in cycles 2-5
- iii. Arm C: Inv. Choice for 6 cycles: R-CHOP or Rituximab-Bendamustine

7. Relapsed and Refractory Follicular or Marginal Zone Lymphoma
8. Diffuse Large Cell, First Line

a. CC-220-DLBCL-001 First line of Therapy

- i. Single arm extension cohort of CC-99282 with the Polatuzumab R-CHP regimen. CC-99282 dose will be determined upon completion of Part 2A and 2B.

9. Mantle Cell Lymphoma

Open 8/13/25

Accrual Goal = 3

Open 3/2/26

CNS (C71)

1. Glioblastoma Multiforme

Leukemia (C91-C92)

1. CLL, First Line
2. CLL, Relapsed or Refractory
3. CML

Myeloma (C90)

1. 1st Line
2. Relapsed / Refractory 1-3 Lines
3. Relapsed / Refractory > or equal to 2 Lines

MDS (D46)

1. 1st Line
2. Observational Registry

Unknown Primary (199)

1. 1st Line

Other

1. Tissue Studies
2. Observational Studies

Multiple Sites

1. Phase I
2. EMD MS100070-0176 (EMR100070-001 Rollover)
3. Novartis Signature Series
4. Solid Tumors, Refractory
5. Solid Tumors, Advanced or Metastatic

Supportive Care

1. Bone Mets
2. Anemia
3. Thrombocytopenia

this list was last updated on: 6/2/26